Sign In
Buy CTLT
$63.49
+0 (+0%)
At Close: Mar 14, 2025
AstraZeneca Seeks Switching COVID-19 Vaccine Production to Catalent Plant: NYT
08:33am, Thursday, 03'rd Jun 2021
AstraZeneca Plc (NASDAQ: AZN) is in talks with the U.S. government to shift production of its COVID-19 vaccine from a troubled Emergent BioSolutions Inc's (NYSE: EBS) Baltimore plant to a factory o
Catalent, Inc. to Present at the Jefferies Healthcare Conference and the William Blair Growth Stock Conference
08:48am, Friday, 28'th May 2021
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gen
Catalent, Inc. to Present at the UBS Global Healthcare Virtual Conference
08:45am, Friday, 21'st May 2021
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gen
Catalent Buys Promethera's Cell Therapy Subsidiary To Scale-Up Plasmid DNA Efforts
03:13pm, Thursday, 06'th May 2021
Catalent Inc (NYSE: CTLT) has been expanding rapidly in next-gen cell therapies, and now it has added another facility in Belgium as part of its plan to bolster its E.U. hub. Catalent has acquired
Catalent, Inc. (CTLT) CEO John Chiminski on Q3 2021 Results - Earnings Call Transcript
12:49pm, Tuesday, 04'th May 2021
Catalent, Inc. (CTLT) CEO John Chiminski on Q3 2021 Results - Earnings Call Transcript
Catalent (CTLT) Tops Q3 Earnings and Revenue Estimates
09:47am, Tuesday, 04'th May 2021
Catalent (CTLT) delivered earnings and revenue surprises of 7.90% and 5.72%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Catalent (CTLT) Expands Deal With Moderna for COVID-19 Vaccine
09:06am, Wednesday, 07'th Apr 2021
Catalent (CTLT) expands its collaboration with Moderna to provide a new high-speed vial filling line for the manufacture of the latter's COVID-19 vaccine.
Catalent to double output of Moderna vaccine: Report
07:14am, Tuesday, 06'th Apr 2021
The U.S. coronavirus vaccine supply could be getting a new boost. According to the Wall Street Journal, contract manufacturer Catalent plans to nearly double its output of the Moderna vaccine, with th
Catalent To Boost Output Of Finished Vials For Moderna's COVID-19 Shot: WSJ
06:46am, Tuesday, 06'th Apr 2021
Catalent Inc (NYSE: CTLT) is reportedly expanding its U.S. production of Moderna Inc's (NASDAQ: MRNA) COVID-19 vaccine to ensure the U.S. has ample supply as it ramps up vaccinations. Catalent hel
Contract drug maker Catalent to double production of Moderna COVID vaccine: WSJ
06:24am, Tuesday, 06'th Apr 2021
Catalent Inc. , a contract drug manufacturer, is expanding U.S. production of the COVID-19 vaccine developed by Moderna Inc. and will nearly double production at its Bloomington, Ind. plant to about 4
Time to Focus on Catalent (CTLT) for Strong Earnings Growth Potential
10:37am, Thursday, 25'th Mar 2021
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Catalent (CTLT).
J&J COVID-19 Vaccine To Get Supply Boost As Manufacturing Partner Catalent Secures Key FDA Clearance
02:13am, Wednesday, 24'th Mar 2021
Johnson & Johnson's (NYSE: JNJ) COVID-19 vaccine is expected to get a significant supply boost after manufacturing partner Catalent Inc (NYSE: CTLT) secured a key U.S. regulator clearance, Bloomberg
7 Growth Stocks With Compelling Stories
11:55am, Wednesday, 17'th Mar 2021
Despite occasional pullbacks in share price, these growth stocks are expected to continue to create shareholder value during the year. The post 7 Growth Stocks With Compelling Stories appeared first o
Catalent to ramp up J&J vaccine production at Italian plant
11:46am, Wednesday, 17'th Mar 2021
Catalent is scaling up manufacturing capacity for Johnson & Johnson's COVID-19 vaccine at its Italian plant, addressing some concerns over the drugmaker's ability to meet vaccine supply targets in the
Catalent plans to expand production of J&J COVID-19 vaccine in Italy: WSJ
09:19pm, Tuesday, 16'th Mar 2021
Catalent Inc plans to expand its COVID-19 vaccine production in Europe that will enable it to make more doses of Johnson & Johnson's shot, the Wall Street Journal reported https://www.wsj.com/articles
